Journal of Medicinal Chemistry · 2010 · 264 citations · 9 references
PharmacyMedicinal ChemistryPharmacologyCancer PharmacologyDrug DiscoveryStructure-activity RelationshipsLead Compound DesignNatural Product Drug DiscoveryProstate CancerQuantitative Structure-activity RelationshipsStructure-activity Relationship AnalysisAndrogen PharmacologyAndrogen Receptor TargetingCastration-resistant Prostate Cancer TherapyChemical Structure-activity RelationshipsProstate Cancer Hormonal TherapyProstate Cancer Hormone TherapySteroid Receptor Antagonists
A structure-activity relationship study was carried out on a series of thiohydantoins and their analogues 14 which led to the discovery of 92 (MDV3100) as the clinical candidate for the treatment of hormone refractory prostate cancer.
9
Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
Chris Tran, Samedy Ouk, Nicola J. Clegg et al. · Science · 2009 · 2.3K citations · Full text
Molecular determinants of resistance to antiandrogen therapy
Charlie D. Chen, Derek S. Welsbie, Chris Tran et al. · Nature Medicine · 2003 · 2.3K citations
Medicine, Endocrinology, Urology +17
John S. Sack, Kevin Kish, Chihuei Wang et al. · Proceedings of the National Academy of Sciences · 2001 · 485 citations · Full text